Anebulo Pharmaceuticals, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
OTC.Pink
Anebulo Pharmaceuticals is prioritizing the development of an intravenous selonabant formulation for pediatric cannabis poisoning, while reporting continued operating losses and proposing a reverse stock split to go private.
OTC.Pink
10-K: Anebulo Pharmaceuticals Prioritizes Intravenous Selonabant for Pediatric Cannabis Toxicity Treatment
Anebulo Pharmaceuticals shifts focus to an intravenous formulation of selonabant for pediatric cannabis poisoning, citing faster approval potential and a critical unmet need.